Current Duke Appointments & Affiliations
Assistant Professor of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2023 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Alirocumab plus cemiplimab in immuno-refractory metastatic NSCLC: A single-arm, multi-center, phase 2 study.
Conference Journal of Clinical Oncology · June 1, 2026 2619Background: Immunotherapy resistance remains a significant unmet clinical need for most non-small cell lung cancer (NSCLC) patients. PCSK9 was shown in preclinical models to mediate cancer immunotherapy resistance and may serve as a novel immuno-inhibi ... Full text CiteAlirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.
Journal article Future Oncol · April 2026 Immunotherapy resistance represents a major unmet clinical need for patients with metastatic non-small cell lung cancer (NSCLC). Preclinical studies have identified PCSK9 as an immunosuppressive regulator of antigen presentation, providing a compelling rat ... Full text Link to item CiteData from Oncogenic Mutant <i>p53</i> Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis
Other · March 16, 2026 <div>Abstract<p>Non–small cell lung cancer (NSCLC) cells with oncogenic mutant <i>p53</i> (<i>Onc-p53</i>) alleles exhibit significantly higher levels of proteasome activity, indicating that Onc-p53 induces prote ... Full text CiteRecent Grants
A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression (HARMONi-7)
Clinical TrialPrincipal Investigator · Awarded by Summit Therapeutics Inc. · 2026 - 2031A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-Line Treatment, for Common EGFR-Mutated
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2025 - 2030Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors
Clinical TrialPrincipal Investigator · Awarded by OncoC4 · 2025 - 2029View All Grants
Education
Rostov State Medical University (Russia) ·
2009
M.D.